Brind.

Adagene Inc. announced strategic developments regarding its ADG126 therapy, including FDA alignment, a partnership with Sanofi, and collaboration with Merck's anti-PD-1 therapy.

1 report, 1 independent Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Adagene Inc. announced strategic developments regarding its ADG126 therapy, including FDA alignment, a partnership with Sanofi, and collaboration with Merck's anti-PD-1 therapy.

Who's involved

What this event is mainly about
SanofiMerck

How it developed

Newest first. Tap a step to see who reported it.
  1. Sanofi representative announced to join Adagene’s Scientific Advisory Board.Sub-event
  2. Adagene Inc. announced on July 15, 2025, that it is seeking regulatory approval from the FDA for its therapy, which involves collaboration with Merck.Sub-event
  3. Adagene aligns with FDA on Phase 2/3 design; Sanofi invests; collaboration with Merck underway.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAdagene Reports Six Months 2025 Financial Results and Provides Corporate Updates Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg